pharma · Melanoma · Multiple Myeloma · RNA
Atrium Therapeutics
Atrium Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 10578 Science Center Dr, Suite 125, San Diego, California 92121, US
- Founded
- 2026
- Employees
- 46
- Programs
- 31
- Drugs
- 33
- Patents
- 37
Atrium Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Atrium Therapeutics.
Atrium Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Carboplatin
Atrium Therapeutics
Lung Cancer Stage II
1 trial -
Diclofenac
Atrium Therapeutics
Wobenzym
1 trial -
Elotuzumab
Atrium Therapeutics
Multiple Myeloma
1 trial -
Low-dose ASA
Atrium Therapeutics
Germ Cell Tumor
1 trial -
Metformin Hydrochloride ER
Atrium Therapeutics
Sarcoma Metastatic
1 trial -
Nivolumab
Atrium Therapeutics
Multiple Myeloma
1 trial -
Olutasidenib
Atrium Therapeutics
IDH1 Mutation
1 trial -
Vaccine
Atrium Therapeutics
Pediatric Cancer
1 trial -
anastrozole
Atrium Therapeutics
Female Breast Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Atrium Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.